HZNP - Horizon Therapeutics Public Limited Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.10
-0.53 (-2.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.63
Open24.54
Bid24.11 x 4000
Ask24.12 x 800
Day's Range23.38 - 24.54
52 Week Range16.56 - 29.44
Volume2,791,462
Avg. Volume1,943,045
Market Cap4.456B
Beta (3Y Monthly)1.06
PE Ratio (TTM)100.00
EPS (TTM)0.24
Earnings DateAug 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.70
Trade prices are not sourced from all markets
  • Horizon's NDA for Procysbi New Dosage Form Accepted by FDA
    Zacks16 hours ago

    Horizon's NDA for Procysbi New Dosage Form Accepted by FDA

    The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.

  • Is Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) A Financially Sound Company?
    Simply Wall St.19 hours ago

    Is Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) A Financially Sound Company?

    Investors are always looking for growth in small-cap stocks like Horizon Therapeutics Public Limited Company...

  • Business Wire2 days ago

    Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets

    Horizon Therapeutics plc (HZNP) announced today that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets. If approved by the FDA, this new dosage form would provide another option for patients, in addition to the currently available PROCYSBI delayed-release capsules. The capsules are FDA-approved for children one year of age and older and adults living with nephropathic cystinosis.

  • Business Wire4 days ago

    Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019

    Horizon Therapeutics plc (HZNP) announced today that its second-quarter 2019 financial results will be released on Wednesday, Aug. 7, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com.

  • Business Wire9 days ago

    Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes

    Horizon Therapeutics plc (HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027. Horizon currently expects to use the net proceeds from the offering, together with approximately $65 million in cash on hand, to redeem or prepay $625 million of its outstanding debt, consisting of (i) the outstanding $225 million principal amount of its 6.625% senior notes due 2023, (ii) the outstanding $300 million principal amount of its 8.75% senior notes due 2024 and (iii) $100 million of the outstanding principal amount of senior secured term loans under Horizon’s credit agreement, as well as to pay the related premiums and fees and expenses, excluding accrued interest, associated with the redemption and prepayment.

  • Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
    Zacks9 days ago

    Horizon Therapeutics Files BLA to FDA for Eye Disease Drug

    Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.

  • Business Wire10 days ago

    Horizon Therapeutics plc Announces Proposed Private Offering of Senior Notes

    Horizon Therapeutics plc (HZNP) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027. Horizon currently expects to use the net proceeds from the offering, together with approximately $64 million in cash on hand, to redeem $525 million of its outstanding debt, consisting of the outstanding (i) $225 million principal amount of its 6.625% senior notes due 2023 and (ii) $300 million principal amount of its 8.75% senior notes due 2024, as well as to pay the related premiums, and fees and expenses, excluding accrued interest, associated with the redemption. The proposed redemption of Horizon’s existing senior notes is being conducted to further Horizon’s deleveraging strategy, to reduce interest expense and to extend the maturity of its debt obligations to improve its capital structure.

  • Business Wire10 days ago

    Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)

    Horizon Therapeutics plc announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational medicine teprotumumab for the treatment of active thyroid eye disease .

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily11 days ago

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.

  • Looking For Growth? Take A Look At These Biotechnology Stocks
    Investor's Business Daily11 days ago

    Looking For Growth? Take A Look At These Biotechnology Stocks

    The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.

  • Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?
    Market Realist17 days ago

    Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?

    Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let's study the drivers and risks for both these rare disease players in greater detail.

  • Eyes on Graves’ Initiative Urges Action for People with Graves’ Disease and Thyroid Eye Disease
    Business Wire23 days ago

    Eyes on Graves’ Initiative Urges Action for People with Graves’ Disease and Thyroid Eye Disease

    Today marks the launch of a new patient empowerment and disease education initiative called Eyes on Graves’, created to bring attention, education and resources to people living with Graves’ disease and/or thyroid eye disease (TED). In time for Graves’ Disease Awareness Month in July, Eyes on Graves’ was created through a new collaboration called the Graves’ and TED Council – a group of people living with both diseases and their loved ones whose mission is to raise awareness and understanding of Graves’ disease and TED among physicians, patients and caregivers, leading to improved care and patient support. Eyes on Graves’ is supported by the Graves’ Disease and Thyroid Foundation (GDATF) and Horizon Therapeutics.

  • Is There An Opportunity With Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) 50% Undervaluation?
    Simply Wall St.27 days ago

    Is There An Opportunity With Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) 50% Undervaluation?

    In this article we are going to estimate the intrinsic value of Horizon Therapeutics Public Limited Company...

  • Here’s What Hedge Funds Think About Horizon Therapeutics Public Limited Company (HZNP)
    Insider Monkey29 days ago

    Here’s What Hedge Funds Think About Horizon Therapeutics Public Limited Company (HZNP)

    Does Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why […]

  • Business Wirelast month

    Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy

    Horizon Therapeutics plc (HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout. Treatment with biologic medicines can, in some patients, trigger the body’s immune system to develop anti-drug antibodies. Immunomodulators, such as methotrexate, are often co-prescribed with biologics to help reduce this reaction.

  • Markitlast month

    See what the IHS Markit Score report has to say about Horizon Therapeutics PLC.

    Horizon Therapeutics PLC NASDAQ/NGS:HZNPView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding HZNP are favorable, with net inflows of $2.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wirelast month

    Horizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019

    Horizon Therapeutics plc (HZNP) is elevating the dialogue on gout within the medical and scientific community during the Annual European Congress of Rheumatology (EULAR 2019) with a series of data presentations on gout and its systemic implications. Oral and poster presentations reinforce the increasingly robust evidence linking gout to renal and cardiovascular health risks and raise important clinical considerations in monitoring and tracking patient status beyond joint health over time. “Across a number of independent evaluations, we’re finding important links between gout and other organ system diseases,” said Jeffrey Kent, M.D., senior vice president, medical affairs and outcomes research, Horizon.

  • How Should Investors Feel About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Pay?
    Simply Wall St.last month

    How Should Investors Feel About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Pay?

    In 2008 Tim Walbert was appointed CEO of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). This report will...

  • Business Wire2 months ago

    Horizon Therapeutics plc to Participate in the JMP Securities Life Sciences Conference

    Horizon Therapeutics plc , today announced that the company will participate in the following conference in June:

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of HZNP earnings conference call or presentation 8-May-19 12:00pm GMT

    Q1 2019 Horizon Pharma PLC Earnings Call

  • Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
    Business Wire2 months ago

    Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

    Horizon Therapeutics plc (HZNP) in partnership with Invitae Corporation (NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to people who may have a UCD, including their family members. Horizon’s support of the UCD Genetic Testing Program facilitates the genetic tests and services offered and performed by Invitae.

  • Business Wire2 months ago

    Horizon Named One of the Best Workplaces in Chicago by Great Place to Work® and FORTUNE

    Horizon Therapeutics plc (HZNP) today announced that it has been selected to the FORTUNE and Great Place to Work® 2019 “Best Workplaces in Chicago” list. “We are proud to be recognized as one of the Best Workplaces in Chicago for the third consecutive year,” said Irina Konstantinovsky, executive vice president, chief human resources officer, Horizon.

  • Business Wire2 months ago

    Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout

    Horizon Therapeutics plc (HZNP) today announced the launch of Gout Lies, a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly manage the disease. Through a mix of thought-provoking visuals, expert videos and clinical data, the campaign is designed to inform a modern dialogue about the impact of gout. The goal is to specifically advance the understanding of the complex relationship between pain resolution and gout progression, given the unique mechanism that resolves acute pain in gout often results in patients delaying discussions with the physician.